Glycated hemoglobin, diabetes treatment and cancer risk in type 2 diabetes. A case-control study

• Autorzy: Dabrowski M.
• Języki publikacji: EN

Abstrakty

EN

Introduction: Type 2 diabetes is associated with an increased risk of some types of cancer. Diabetes treatment may also modify cancer risk. Objective: The aim of this retrospective, case-control study was to assess whether HbA1c level and use of anti-diabetic drugs are associated with cancer development in a diabetic population. Materials and methods: The case group consisted of 53 patients who developed cancer after diagnosis of diabetes. They were compared with 53 diabetic subjects without cancer, strictly matched to a case group by age and gender. In both groups – apart from HbA1c and diabetes treatment – demographic data, smoking habits, comorbidities, BMI, diabetes duration, use of aspirin, antihypertensive and hypolipemic drugs were also analyzed. Results: Patients with cancer had a significantly higher mean HbA1c value compared with the control group, 7.83±1.26% vs. 7.30±1.08%, respectively (p=0.022). The distribution of patients in four HbA1c categories (<7.0, 7.0-7.9, 8.0-8.9 and ≥9.0%) was significantly different between the two groups (p=0.031). The probability of cancer was higher among patients with HbA1c value ≥8.0 % OR 3.160 (95% CI 1.342-7.440), p=0.013, and lower among patients using metformin, OR 0.228 (95% CI 0.083-0.633), p=0.006. The number of insulin users, insulin dose, duration of insulin treatment, and use of other anti-diabetic drugs were not significantly different between the two groups. Also, no significant differences were found between the two groups regarding other variables. Conclusions: The presented case-control study indicated an important role of metabolic control and confirmed the protective role of metformin in reducing cancer risk among patients with type 2 diabetes. Contrary to other studies, insulin use was not associated with a higher risk of cancer. Other anti-diabetic drugs appeared to have a neutral impact on cancer development.

• Wydawca: -
• Czasopismo: Annals of Agricultural and Environmental Medicine
• Rocznik: 2013
• Tom: 20
• Numer: 1
• Opis fizyczny: p.116-121,fig.,ref.

Twórcy

autor

Dabrowski M.

• Department of Medicine, Institute of Nursing and Health Sciences, University of Rzeszow, Poland; Diabetic Outpatient Clinic, NZOZ Beta-Med, Rzeszow, Poland

Bibliografia

• 1. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005; 97: 1679-1687.
• 2. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies.Br J Cancer. 2005; 92: 2076-2083.
• 3. Wang P, Kang D, Cao W, Wang Y, Liu Z. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis.Diabetes Metab Res Rev. 2012; 28: 109-122.
• 4. Friberg E, Orsini N, Mantzoros CS, et al. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 2007; 50: 1365-1374.
• 5. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer. 2007; 121: 856-862.
• 6. Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006; 49: 2819-2823.
• 7. Larsson SC, Wolk A. Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies. Diabetologia 2011; 54: 1013-1018.
• 8. Mitri J, Castillo J, Pittas AG. Diabetes and risk of Non-Hodgkin’s lymphoma. A meta-analysis of observational studies. Diabetes Care.2008; 31: 2391-2397.
• 9. Lee S-A. Gene-diet interaction on cancer risk in epidemiological studies. J Prev Med Public Health. 2009; 42: 360-370.
• 10. Dąbrowski M. Cukrzyca a nowotwory (Diabetes and cancer). Diabet Prakt. 2010; 11: 54-63 (in Polish).
• 11. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010; 33: 1674-1685.
• 12. Noto H, Tsujimoto T, Sasazuki T, Noda M. Significantly increased risk of cancer in patients with diabetes mellitus: a systematic review andmeta-analysis. Endocr Pract. 2011; 17: 616-628.
• 13. Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L, Renehan AG. Diabetes and cancer (1): evaluating a temporal relationship betweentype 2 diabetes and cancer incidence. Diabetologia 2012; 55: 1607-1618.
• 14. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg Effect: The metabolic requirements of cell proliferation.Science 2009; 324: 1029-1033.
• 15. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with Glucagon-Like Peptide-1–basedtherapies. Gastroenterology 2011; 141: 150-156.
• 16. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinalcohort study. Diabetes Care. 2011; 34: 916-922.
• 17. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients inFrance: a population-based cohort study. Diabetologia 2012; DOI10.1007/s00125-012-2538-9 (accessed: 20 June 2012).
• 18. Heuson JC, Legros N, Heimann R. Influence of insulin administration on growth of the 7,12-dimethylbenz(a)anthracene-induced mammarycarcinoma in intact, oophorectomized, and hypophysectomized rats.Cancer Res. 1972; 32: 233-238.
• 19. Rapp K, Schroeder J, Klenk J, et al. Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia2006; 49: 945-952.
• 20. Stattin P, Björ O, Ferrari P, et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care. 2007; 30: 561-567.
• 21. Stocks T, Rapp K, Bjørge T, et al. Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (Me-Can): analysis of six prospective cohorts. PLoS Med. 2009 Dec; 6(12):e1000201. Epub 2009 Dec 22.
• 22. Stocks T, Lukanova A, Johansson M, et al. Components of the metabolic syndrome and colorectal cancer risk; a prospective study. Int J Obes.2008; 32: 304-314.120
• 23. Khaw K-T, Wareham N, Bingham S, Luben R, Welch A, Day N. Preliminary communication: glycated hemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysisfrom the European prospective investigation into Cancer–NorfolkStudy. Cancer Epidemiol Biomarkers Prev. 2004; 13: 915-919.
• 24. Rinaldi S, Rohrmann S, Jenab M, et al. Glycosylated hemoglobin and risk of colorectal cancer in men and women, the European ProspectiveInvestigation into Cancer and Nutrition. Cancer Epidemiol BiomarkersPrev. 2008; 17: 3108-3115.
• 25. Joshu CE, Prozment AE, Dluzniewski PJ, et al. Glycated hemoglobin and cancer incidence and mortality in the Atherosclerosis in Communities(ARIC) Study, 1990-2006. Int J Cancer. doi: 10.1002/ijc.27394, publishedonline 10 Feb 2012. (accessed 20 June 2012).
• 26. Donadon V, Balbi M, Valent F, Avogaro A. Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma.World J Gastroenetrol. 2010; 16: 3025-3032.
• 27. Yang Y-X, Habel LA, Capra AM, et al. Serial glycosylated hemoglobin levels and risk of colorectal neoplasia among patients with type 2diabetes mellitus. Cancer Epidemiol Biomarkers Prev. 2010; 19: 3027-3036.
• 28. Lin J, Ridker PM, Rifai N, et al. A prospective study of hemoglobin 1c concentrations and risk of breast cancer in women. Cancer Res.2006; 66: 2869-2875.
• 29. Becker S, Dossus L, Kaaks R. Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arch Physiol Biochem. 2009;115: 86-96.
• 30. Riehl A, Németh J, Angel P, Hess J. The receptor RAGE: Bridging inflammation and cancer. Cell Commun Signal. 2009; 7: 12;doi:10.1186/1478-811X-7-12 (accessed 20 June 2012).
• 31. Polskie Towarzystwo Diabetologiczne. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę, 2012. Diabetologia Klin. 2012;1 (supl. A) (in Polish).
• 32. American Diabetes Association. Clinical practice recommendations 2012. Diabetes Care. 2012; 35 (Suppl.1).
• 33. Inzucchi SE, Bergenstal RM, Buse JB,et al. Management of hyperglycemia in type 2 diabetes: a patient centered approach. Position statement of the American Diabetes Association (ADA) and the European Associationfor the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1596.
• 34. Gallagher EJ, LeRoith D. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann NY Acad Sci. 2011; 1243:54-68.
• 35. Aljada A, Mousa SA. Metformin and neoplasia: Implications and indications. Pharmacol Ther. 2012; 133: 108-115.
• 36. Janghorbani M, Dehghani M, Salehi-Marzijarani M. Systematic review and meta-analysis of insulin therapy and risk of cancer. Horm Cancer.2012; DOI: 10.1007/s12672-012-0112-z, April 24 (accessed 20 June 2012).
• 37. Bhartia M, Tahrani AA, Barnett AH. SGLT-2 inhibitors in development for type 2 diabetes treatment. Rev Diabet Stud. 201; 8: 348-354.
• 38. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569-578.

Uwagi

rekord w opracowaniu